Compare DDS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DDS | ABVX |
|---|---|---|
| Founded | 1938 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 9.0B |
| IPO Year | N/A | N/A |
| Metric | DDS | ABVX |
|---|---|---|
| Price | $626.58 | $139.31 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $511.33 | $115.83 |
| AVG Volume (30 Days) | 140.4K | ★ 1.8M |
| Earning Date | 11-13-2025 | 08-11-2025 |
| Dividend Yield | ★ 5.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 36.93 | N/A |
| Revenue | ★ $6,625,563,000.00 | $6,231,374.00 |
| Revenue This Year | $0.60 | $6.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $282.24 | $4.77 |
| 52 Week High | $741.98 | $139.62 |
| Indicator | DDS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 66.74 |
| Support Level | $602.75 | $108.53 |
| Resistance Level | $663.58 | $138.49 |
| Average True Range (ATR) | 27.22 | 7.32 |
| MACD | -10.47 | 0.89 |
| Stochastic Oscillator | 17.00 | 91.28 |
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.